



Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Ubrelvy (urbrogepant) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 4 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Ubrelvy (urbrogepant)**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: [1-866-331-2104](tel:1-866-331-2104)]. If you have any questions or concerns, please call [1-866-331-2103](tel:1-866-331-2103). **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: <http://www.providers.kaiserpermanente.org/mas/formulary.html>**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Is the prescriber a neurologist or pain management specialist with expertise in diagnosis/treating headache ? ☐ No ☐ Yes

If consulted with a specialist, specialist name and specialty: _____

Provider Name: _____ Specialty: _____ NPI: _____

Provider Address: _____

Provider Phone #: _____ Provider Fax #: _____

Please check the boxes that apply:

☐ Initial Request ☐ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone # _____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5– Diagnosis/Clinical Criteria

Initial Therapy:

1. Is the member's age ≥ 18 years or ≤ 75 years? **AND**
☐ No ☐ Yes
2. Use is for treatment of migraine **AND**
☐ No ☐ Yes
3. Either
 - a) Documented trial (≥ 2 months) with treatment failure, or inadequate response, to at least 3 generic oral triptan agents at maximally tolerated doses, **OR**
☐ No ☐ Yes
 - b) Documented trial (≥ 2 months) with treatment failure, inadequate response, or contraindication to use to at least 3 preventative agents for migraine, 2 of which must include:
 - Tricyclic antidepressants (e.g., amitriptyline, nortriptyline)
 - Beta-blocker (e.g., metoprolol, propranolol)
 - Topiramate
 - Valproate☐ No ☐ Yes

Continuation of Therapy:

1. After 3 months of treatment patient has positive clinical response.
☐ No ☐ Yes

7 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:

Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility